According to filings with the U.S. Securities and Exchange Commission, Glycotest is raising up to $6,798,345.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Glycotest
Glycotest is a liver disease diagnostics company focused on developing and commercializing unique, non-invasive blood tests for life threatening liver cancers and progressive fibrosis cirrhosis. The companys technology measures sugar based disease signals on serum glycoproteins to provide information on the likelihood of serious liver disease, with a lead test for curable early stage liver cancer that has significantly outperformed the current standard blood test in multiple preliminary clinical studies. Founded in 2012 by NetScientific plc on technology innovated at Drexel University College of Medicine and the Baruch S. Blumberg Institute, Glycotest holds exclusive worldwide rights to more than 50 patent protected serum glycoprotein biomarkers, biomarker panels, algorithms, and novel assay technologies. Its mission is to revolutionize the care and treatment of people at risk due to chronic liver disease, including patients with viral hepatitis B and C and the rapidly growing population with non viral hepatitis related to obesity and metabolic disease. By creating new clinical laboratory testing services that exploit sugar based disease signals, Glycotest aims to improve early detection, surveillance, and outcomes for patients facing serious liver diseases such as hepatocellular carcinoma and fibrosis cirrhosis.

To learn more, visit https://www.glycotest.com/
LinkedIn: https://www.linkedin.com/company/glycotest-inc.

Contact:
Charles Swindell, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.